Literature DB >> 11466673

The development of breast carcinoma in women with thyroid carcinoma.

A Y Chen1, L Levy, H Goepfert, B W Brown, M R Spitz, R Vassilopoulou-Sellin.   

Abstract

BACKGROUND: Breast carcinoma and thyroid carcinoma are two malignancies that occur most commonly in women. An association between the incidence rates of thyroid and breast carcinoma in women after a diagnosis of the other malignancy has been suggested in a retrospective analysis of a single institution's tumor registry. In that study, an increased incidence of breast carcinoma in premenopausal women previously treated for thyroid carcinoma was observed.
METHODS: The purpose of this study was to investigate further this relation utilizing a large database, the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database. The SEER database is maintained by the National Cancer Institute, and it represents 11 population-based cancer registries covering approximately 14% of the United States population. The study was a population-based retrospective cohort analysis using external comparisons. From 1973 to 1994, 365 women in the SEER database were identified as having both thyroid and breast carcinomas. The SEER database from 1973 to 1994 was utilized to calculate age specific and calendar year specific incidence rates for each year for thyroid and breast carcinomas. The expected number of second cancers for each age group, calendar year, and follow-up period were determined by multiplying these incidence rates by the age specific and calendar year specific number of person-years at risk. The risk ratio (RR) was calculated by dividing the observed by the expected number of second cancers. Statistical significance was determined by the Poisson test.
RESULTS: A total of 1,333,115 person-years were available for analysis. One hundred thirteen thyroid carcinoma cases were diagnosed after breast carcinoma cases (RR, 0.99; P = 0.576). Two hundred fifty-two breast carcinoma cases were diagnosed after thyroid carcinoma cases (RR, 1.18; P = 0.007). Premenopausal women (age 20-49 years) with an index thyroid carcinoma have a significantly increased risk of developing subsequent breast carcinoma (RR, 1.42; P = 0.001). Black premenopausal women with an index thyroid carcinoma do not have an increased risk of developing breast carcinoma, but the statistical power is lower due to low numbers. No women with index breast carcinoma have an increased risk of developing thyroid carcinoma.
CONCLUSIONS: Women with a history of thyroid carcinoma have a greater than expected risk of developing breast carcinoma. This risk is most pronounced in premenopausal white women. The implications of this observation with respect to breast carcinoma screening guidelines and thyroid carcinoma treatment guidelines deserve further investigation. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11466673     DOI: 10.1002/1097-0142(20010715)92:2<225::aid-cncr1313>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  31 in total

1.  Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer.

Authors:  Fabrizio Consorti; Gianluca Di Tanna; Francesca Milazzo; Alfredo Antonaci
Journal:  World J Surg Oncol       Date:  2011-08-12       Impact factor: 2.754

2.  Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS).

Authors:  Xi Wei; Ying Li; Sheng Zhang; Gao Ming
Journal:  Tumour Biol       Date:  2014-04-01

Review 3.  The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis.

Authors:  Sarah M Nielsen; Michael G White; Susan Hong; Briseis Aschebrook-Kilfoy; Edwin L Kaplan; Peter Angelos; Swati A Kulkarni; Olufunmilayo I Olopade; Raymon H Grogan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02       Impact factor: 4.254

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

5.  A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer.

Authors:  Carolina Pires; Inês Jorge Marques; Daniela Dias; Ana Saramago; Valeriano Leite; Branca Maria Cavaco
Journal:  Endocrine       Date:  2021-03-08       Impact factor: 3.633

6.  Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population-based case-control study in New Caledonia (South Pacific), a very high incidence area.

Authors:  Thérèse Truong; Laurent Orsi; Dominique Dubourdieu; Yannick Rougier; Denis Hémon; Pascal Guénel
Journal:  Am J Epidemiol       Date:  2005-06-01       Impact factor: 4.897

Review 7.  Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity.

Authors:  Nicholas S Andresen; John M Buatti; Hamed H Tewfik; Nitin A Pagedar; Carryn M Anderson; John M Watkins
Journal:  Eur Thyroid J       Date:  2017-03-23

8.  Mediastinal metastasis of the thyroid papillary carcinoma mimicking thymoma.

Authors:  Masaya Okuda; Hiroyasu Yokomise; Sung-soo Chang; Jun Nakano; Noriyuki Misaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-10-15

9.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

10.  Unbalanced estrogen metabolism in thyroid cancer.

Authors:  Muhammad Zahid; Whitney Goldner; Cheryl L Beseler; Eleanor G Rogan; Ercole L Cavalieri
Journal:  Int J Cancer       Date:  2013-06-14       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.